Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
6.15 p
0.00 p(0.00%)
At close: 4:00 PM EDT
6.15 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range2.84 p - 9.00 p
Previous CloseN/A
Volume885.20K
Average Volume (3M)1.12M
Market Cap
£62.60M
Enterprise Value20.18 p
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding763,437,130
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory/Clinical ReadinessTOPICAL being fully prepared with MHRA approval, six UK sites and in-kind supply of teclistamab materially reduces execution risk and accelerates enrollment. This readiness improves probability of generating meaningful interim data and strengthens negotiating leverage with partners over the next 2–6 months.
Strong Early Pharmacology SignalRobust cytokine suppression in a placebo-controlled human LPS challenge provides durable mechanistic validation and target engagement. Such clear translational signals support de-risking of clinical hypotheses, strengthen case for partners and payers, and underpin longer-term development plans beyond initial readouts.
Near-term Funding And GrantsHaving ~£7.7m and recent successful fundraising plus a £3.4m RISE grant provides a tangible runway to execute the TOPICAL study and initial GLP‑1 work. This near-term funding reduces immediate dilution risk and enables delivery of catalytic data that can materially change financing and partnering dynamics.
Bears Say
Pre‑revenue Loss ProfileThe company remains pre‑revenue with multi-year operating losses and negative cash flows, which structurally increases reliance on external capital. Persistent losses erode equity and limit flexibility, making long‑term execution contingent on successful financings, partnerships or milestone monetization.
Limited Trial DesignA small, single‑arm open‑label TOPICAL study restricts the strength of efficacy claims and may require larger randomized trials for regulatory and payer acceptance. This design increases the probability of needing follow‑on studies and additional funding to secure late‑stage development or commercialization deals.
Funding Horizon & Partner DependenceRunway into 2027 and explicit dependence on partners for late‑stage development create structural execution risk: the company must secure partnerships or fresh capital to fund pivotal trials and commercialization. This reliance can delay programs or dilute existing shareholders if terms are suboptimal.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.84 p and its highest was 9.00 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £62.60M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 26 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―